Foreign-Trade Zone (FTZ) 61, Notification of Proposed Production Activity; Viatris Pharmaceuticals LLC; (Medications); Vega Baja, Puerto Rico

Viatris Pharmaceuticals LLC submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Vega Baja, Puerto Rico within FTZ 61. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on July 30, 2026.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/​ftz.

The proposed finished products include: ativan talbets, atorvastatin tablets, celebrex capsules; colestid tablets; Detrol capsules; Dilantin tablets and capsules; Effexor capsules; eplerenone tablets; ibrance capsules; inspra tablets; Lipitor tablets; lorbrena tablets; lorviqua tablets; lyrica capsules; Neurontin tablets and capsules; nitrostat tablets; Norvasc tablets; Pristiq tablets; vizimpro tablets; Xanax immediate release tablets; Xeljanz extended release tablets; Zithromax tablets; and zyvox tablets (duty-free).

The proposed foreign-status materials/components include: amlodipine besylate active pharmaceutical ingredient (API); atorvastatin API; Ativan tablets; azithromycin API; calcium carbonate; Cardura bulk tablets; celecoxib API; dacomitinib tablets; Effexor capsules; eplerenone API; gabapentin API; Geodon capsules; microcrystalline cellulose; mini bags; pharmatose (lactose for atorvastatin/Lipitor); pregabalin API; propranolol API; pregabalin bulk capsules; rapamune tablets; tabbletose; Xanax IR tablets; Xanax XR tablets; Zoloft tablets; disopyramide API; linezolid API; lorlatinib tablets; palbociclib tablets; Pristiq tablets; rapamune tablets; and, talazoparib tablets (duty rate ranges from duty-free to 8.4%).

The request indicates that certain materials/components are subject to duties under section 232 of the Trade Expansion Act of 1962 (section 232), depending on the country of origin. The applicable section 232 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is September 21, 2026.

A copy of the notification will be available for public inspection in the “Online FTZ Information System” section of the Board's website.

For further information, contact Brian Warnes at brian.warnes@trade.gov.